系统性和向性类固醇用于治疗IgA脏病
Francesco Locatelli1, Lucia Del Vecchio2, Claudio Ponticelli
1Department of Nephrology and Dialysis, Alessandro Manzoni Hospital, Lecco, Italy.
Clinical kidney journal
|December 6, 2023
概括
定向释放配方 (TRF) budesonide通过减少蛋白尿和副作用,对免疫球蛋白A脏病 (IgAN) 显示出希望. 需要进一步的长期研究来确认其与当前治疗相比的疗效.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫球蛋白A脏病 (IgAN) 是渐进性功能衰竭的常见原因,影响30-50%的末期病患者 (ESKD).
- 目前的治疗方法,包括全身葡萄糖皮质类药物,具有不确定的疗效和潜在的副作用.
- 优化的支持性护理与氨酸-血管新生素系统 (RAS) 阻断和SGLT2抑制剂是主要的管理重点.
研究的目的:
- 评估用于治疗IGAN的新型定向释放配方 (TRF) 的疗效和安全性.
- 评估TRF-budesonide是否可以减少蛋白尿和损伤,同时最大限度地减少全身类固醇副作用.
主要方法:
- 两项临床试验研究了TRF-budesonide对Igan患者的影响.
- 这项研究的重点是药物的局部输送到远端大肠,以减轻系统性不良事件.
主要成果:
- 在接受治疗的患者中,TRF-budesonide显著降低了蛋白尿和血尿.
- 该配方可能会保持功能,并显著减少与全身类固醇相关的副作用.
- 初步发现表明,Igan治疗具有有希望的局部疗效.
结论:
- TRF-budesonide显示出作为Igan的新型治疗方法的潜力,可以减少副作用.
- 然而,有限的患者数量和短时间的随访需要谨慎;需要长期的数据和对全身类固醇的头对头试验.
- TRF-budesonide尚未被认为是Igan脏病治疗的标准治疗方法.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
270
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
270
01:29Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143